DRC approves Merck vaccine for use in Ebola outbreak

The Democratic Republic of the Congo approved a protocol to use Ebola vaccine rVSV-ZEBOV (V920) from Merck & Co. Inc. (NYSE:MRK) on the heels of last week’s declaration by the

Read the full 303 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE